tirzepatide delivered to your door 🚀 STOP THE GLP-1 SHORTAGE

Doi:10.1046/j.1523-1747.1999.00708.x Ionescu M, Frohman LA

The program is designed for convenience and fast access, helping patients begin treatment quickly while minimizing in-person barriers

Patients carrying certain alleles may have naturally higher GLP-1 receptor sensitivity, potentially achieving robust results at 0.25mg, while others may require escalation to unlock adequate appetite suppression

The flexible dosing regimen allows clinicians to optimize therapy based on individual metabolic response and liver health markers, rather than forcing patients into fixed FDA-approved increments

Marked insulinotropic effects have been observed in T2DM patients with a single injection of liraglutide (120) or acute infusion of exenatide (121)

Earlier weight loss therapies focused mainly on reducing appetite